Anti-TNF therapeutics target an important driver of the chronic inflammatory response [106, 107] and have had success in the clinic, but patients on this therapy are at increased risk of infection [108], and 80% fail to achieve long-term remission and relapse within one year [109]. This evidence concerns the gene TNF and infection.